New Findings Recommend Oestrogen Therapy After Surgical Menopause
Published: 16th June 2020
New findings, published by Yale University Professor Philip Sarrel, recommend oestrogen therapy after surgical menopause as a way to effectively control symptoms, as well as reducing the risk of future disease. In this article, Prof Sarrel also explores how HRT can reduce medical expenditure for women following a hysterectomy.
“Menopause” is a monthly medical journal published by the North American Menopause Society. After editorial review, it publishes new findings from studies by the world’s leading scientific researchers. Menopause journal, in its more than 25 years of publication, has gained recognition as one of the most respected and highly rated of medical journals.
The June 2020 issue of Menopause journal contains a new article based on long-term data (18 year follow-up) from the Women’s Health Initiative (WHI) Studies. The authors select out the data for women who initiated estrogen therapy following hysterectomy and or removal of their ovaries before age 60. For these women, using estrogen therapy reduced disease risks for coronary heart disease, breast cancer, colorectal cancer, hip fracture, and stroke.
Earlier reports from the WHI study showed the use of estrogen therapy before age 60 reduced mortality due to breast cancer, heart disease and Alzheimer’s disease (Manson J and others, Ann Intern Med. 2019; LaCroix A and others, JAMA 2011). The findings are consistent with the 30 year follow-up studies from the Mayo Clinic Oophorectomy Study. That study also adds reduced risk for dementia when women initiate estrogen therapy at the time of surgery and continue for 10 years or more.
Disease risk and mortality rates before age 70 are increased following surgical menopause without hormone therapy. Women and healthcare providers think and use hormone therapy primarily for control of symptoms due to menopause. It is as, if not more, important to realize estrogen therapy in particular should be used for disease prevention and extending life expectancy.
The Menopause: June 2020 issue also carries an Invited Editorial by Yale Professor Philip Sarrel which comments on the new WHI findings and expands upon the issues of reducing medical expenditures and disease prevention through the use of estrogen therapy.
Further discussion by Professor Sarrel is available on the empowHER website.